Apellis Pharmaceuticals (APLS) - יתרות מזומנים בחישוב למניה

Apellis Corp - לוגו גרפי של המנפיק APLS

Cash per share for Apellis Pharmaceuticals (APLS) demonstrates a liquidity evolution from a baseline reduction in laboratory plastics to current values. The 3.18 metric serves as the parameter's base value, confirming financial stability. Apellis Pharmaceuticals diversifies risks through therapies for rare vision and blood pathologies, integrating ESG principles into the development of safe medications to ensure treatment accessibility.

מזומנים למניה אחת Apellis Pharmaceuticals, Inc. (APLS): לתקופה 04.07.2022 - 30.05.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Apellis (APLS)

- מדדי זמינות כספים ותזרימי מזומנים:
ניתוח מסכם של החברה:APLS, Apellis Corp
מוצרים מיוצרים של apellis.com

Stable demand for Apellis Pharmaceuticals (APLS) ophthalmology therapies generates a steady cash flow, which is reflected in the current cash per share value of 3.18. This indicator determines the portion of liquid capital per share, allowing investors to assess the company's resilience during a crisis or identify inefficient resource accumulation that reduces the overall return on investment.